[ Vivet Therapeutics raises $40.9M in Series A ]

Vivet Therapeutics has raised $40.9 million in Series A funding.

Founded in 2016, Vivet Therapeutics  is engaged in developing and commercializing gene therapies for the treatment of liver disorders and orphan diseases.

The funds will be used by Vivet to advance a diversified pipeline of gene therapy programs targeting rare, inherited metabolic diseases, including Wilson Disease, progressive familial intrahepatic cholestasis type 2 (PFIC2), progressive familial intrahepatic cholestasis type 3 (PFIC3) and citrullinemia type I.

Funding  Series A
Founded  2016
Country  France
City  Paris, Ile-de-France
Founder / CEO  Jean Philippe Combal
Deal Size  $40.9M
Investors  Novartis Venture Fund
 Columbus Venture Partners
 Ysios Capital
 HealthCap
 Roche Venture Fund
Previous Investors  /

[adyen action=”checkout_button”]